Drug resistance and Cancer stem cells.
Drug resistance and Cancer stem cells.
复制标题
DOI：
10.1186/s12964-020-00627-5
复制
发表时间：
2021-02-15
期刊：
影响因子：
--
通讯作者：
Song S
中科院分区：
文献类型：
--
作者：
Li Y;Wang Z;Ajani JA;Song S
在治疗癌症患者时，治疗抗性是一个主要问题，因为癌细胞会形成一些机制来抵消治疗化合物的作用，从而产生适应性更强且更具侵袭性的克隆，导致预后不良。治疗抗性可以是内在的和/或后天获得的。这些是多因素事件，其中一些与多种因素有关，包括癌症干细胞（CSCs）的适应性、上皮 - 间质转化（EMT）、关键信号通路的失调、通过ABC转运蛋白的药物外排、获得性突变、逃避细胞凋亡以及DNA损伤反应的激活等。在这些因素中，癌症干细胞是治疗抗性的主要来源。癌症干细胞是肿瘤细胞的一个子集，能够自我更新和多谱系祖细胞扩增，已知其对抗癌治疗具有内在抗性。癌症干细胞的多个克隆预先存在，并且一些克隆能够容易地适应并随着肿瘤微环境（TME）的变化和/或对放疗和化疗做出反应而扩增。内在和外在因素共同导致了癌症干细胞介导的治疗抗性。在这篇综述中，我们将重点关注癌症干细胞和治疗抗性，并提出消除癌症干细胞从而克服抗性的策略。
视频摘要。
网络版包含补充材料，可在10.1186/s12964 - 020 - 00627 - 5获取。
Therapy resistance is a major problem when treating cancer patients as cancer cells develop mechanisms that counteract the effect of therapeutic compounds, leading to fit and more aggressive clones that contribute to poor prognosis. Therapy resistance can be both intrinsic and/or acquired. These are multifactorial events, and some are related to factors including adaptations in cancer stem cells (CSCs), epithelial-mesenchymal transition (EMT), deregulation of key signaling pathways, drug efflux through ABC transporters, acquired mutations, evading apoptosis, and activation of DNA damage response among others. Among these factors, CSCs represent the major source of therapy resistance. CSCs are a subset of tumor cells that are capable of self-renewal and multilineage progenitor expansion that are known to be intrinsically resistant to anticancer treatments. Multiple clones of CSCs pre-exist, and some can adopt and expand easily to changes in the tumor microenvironment (TME) and/or in response to radio- and chemotherapy. A combination of both intrinsic and extrinsic factors contributes to CSC-mediated therapy resistance. In this review, we will focus on CSCs and therapy resistance as well as suggest strategies to eliminate CSCs and, therefore, overcome resistance. Video abstract. The online version contains supplementary material available at 10.1186/s12964-020-00627-5.
登录
查看更多内容
影响因子：
50.3
作者：
Domingo-Domenech J;Vidal SJ;Rodriguez-Bravo V;Castillo-Martin M;Quinn SA;Rodriguez-Barrueco R;Bonal DM;Charytonowicz E;Gladoun N;de la Iglesia-Vicente J;Petrylak DP;Benson MC;Silva JM;Cordon-Cardo C
通讯作者：
Cordon-Cardo C
影响因子：
8.4
作者：
Collins, Anne T.;Maitland, Norman J.
通讯作者：
Maitland, Norman J.
Musashi 2通过LIN28A激活促进肝癌干细胞的干性和化疗耐药性
影响因子：
9.7
作者：
Fang, Tian;Lv, Hongwei;Wang, Hongyang
通讯作者：
Wang, Hongyang
影响因子：
5.7
作者：
Das, Sreemanti;Mukherjee, Pritha;Chatterji, Urmi
通讯作者：
Chatterji, Urmi
影响因子：
2.4
作者：
Fu Y;Du P;Zhao J;Hu C;Qin Y;Huang G
通讯作者：
Huang G